UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics

Fibrinolysis & proteolysis, 1997-05, Vol.11 (3), p.129-135

1997

Volltextzugriff (PDF)

The spectroscopic analysis, inhibition and binding studies demonstrate the equivalence of Erythrina caffra trypsin inhibitor and the recombinant substitution variant recSerETI

Journal of biotechnology, 1998-07, Vol.62 (3), p.231-239

1998

Volltextzugriff (PDF)

Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis

Thrombosis and haemostasis, 1991-05, Vol.65 (5), p.560-564

1991

Volltextzugriff (PDF)

Coronary Thrombolytic Properties of a Novel Recombinant Plasminogen Activator (BM 06.022) in a Canine Model

Journal of cardiovascular pharmacology, 1991-07, Vol.18 (1), p.111-119

1991

Volltextzugriff (PDF)

Formulation of Proteins in Vacuum-Dried Glasses. II. Process and Storage Stability in Sugar-Free Amino Acid Systems

Pharmaceutical development and technology, 1999, Vol.4 (2), p.199-208

1999

Volltextzugriff (PDF)

LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate

Clinica chimica acta, 1984-06, Vol.140 (1), p.77-83

1984

Volltextzugriff (PDF)

The 2.3 Å Crystal Structure of the Catalytic Domain of Recombinant Two-chain Human Tissue-type Plasminogen Activator

Journal of molecular biology, 1996-04, Vol.258 (1), p.117-135

1996

Volltextzugriff (PDF)

Mapping of the catalytic site of CHO‐t‐PA and the t‐PA variant BM 06.022 by synthetic inhibitors and substrates

Protein science, 1992-08, Vol.1 (8), p.1007-1013

1992

Volltextzugriff (PDF)

Tissue kallikrein effectively activates latent matrix degrading metalloenzymes

Advances in experimental medicine and biology, 1989, Vol.247A, p.545

1989

Volltextzugriff (PDF)

Pharmacokinetic properties of an escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits

Thrombosis research, 1991-05, Vol.62 (3), p.137-146

1991

Volltextzugriff (PDF)

Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA

The EMBO journal, 1997-08, Vol.16 (16), p.4797-4805

1997

Volltextzugriff (PDF)

Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli

Naunyn-Schmiedeberg's archives of pharmacology, 1992-07, Vol.346 (1), p.108-113

1992

Volltextzugriff (PDF)

Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors

The Journal of biological chemistry, 1997-08, Vol.272 (35), p.21713-21719

1997

Volltextzugriff (PDF)

The Effects of Tween 20 and Sucrose on the Stability of Anti‐L‐Selectin during Lyophilization and Reconstitution

Journal of pharmaceutical sciences, 2001-10, Vol.90 (10), p.1466-1477

2001

Volltextzugriff (PDF)

The interaction of recombinant tissue type plasminogen activator and recombinant plasminogen activator (r-PA/BM 06.022) with human endothelial cells

Blood coagulation & fibrinolysis, 1997-03, Vol.8 (2), p.124-133

1997

Volltextzugriff (PDF)

Binding of recombinant variants of human tissue-type plasminogen activator (t-PA) to human umbilical vein endothelial cells

Thrombosis research, 1992-09, Vol.67 (5), p.589-599

1992

Volltextzugriff (PDF)

Pharmacokinetic and preclinical studies with reteplase

Drugs of today (Barcelona, Spain : 1998), 1997, Vol.33 (9), p.633

1997

Volltextzugriff (PDF)

The degradation of collagen by a metalloproteinase from human leucocytes

Advances in experimental medicine and biology, 1988, Vol.240, p.33

1988

Volltextzugriff (PDF)

Effect of disulfide bonds on the structure, function, and stability of the trypsin/tPA inhibitor from Erythrina caffra : Site-directed mutagenesis, expression, and physiochemical characterization

Nature biotechnology, 1996-04, Vol.14 (4), p.476-480

1996

Volltextzugriff (PDF)

Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022

Protein engineering, 1992-01, Vol.5 (1), p.93-100

1992

Volltextzugriff (PDF)

Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis

Thrombosis and haemostasis, 1996-12, Vol.76 (6), p.1096-1101

1996

Volltextzugriff (PDF)

The spectroscopic analysis, inhibition and binding studies demonstrate the equivalence of Erythrina caffra trypsin inhibitor and the recombinant substitution variant recSerETI1Dedicated to Prof. Maria-Regina Kula on the ocasion of her 60th birthday1

Journal of biotechnology, 1998-07, Vol.62 (3), p.231-239

1998

Volltextzugriff (PDF)

The recombinant Escherichia coli-derived protease-domain of tissue-type plasminogen activator is a potent and fibrin specific fibrinolytic agent

Fibrinolysis, 1996-03, Vol.10 (2), p.93-102

1996

Volltextzugriff (PDF)

spectroscopic analysis, inhibition and binding studies demonstrate the equivalence of Erythrina caffra trypsin inhibitor and the recombinant substitution variant recSerETl

Journal of biotechnology, 1998, Vol.62 (3), p.231-239

1998

Volltextzugriff (PDF)

A variant of tissue plasminogen activator (t-PA) comprised of the Kringle 2 and the protease domain shows a significant difference in the in vitro rate of plasmin formation as compared to the recombinant human t-PA from transformed chinese hamster ovary cells

Fibrinolysis, 1993-11, Vol.7 (6), p.365-372

1993

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(38)

Publikationsform

Sprache

Englisch
(46)
Deutsch
(6)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics

The spectroscopic analysis, inhibition and binding studies demonstrate the equivalence of Erythrina caffra trypsin inhibitor and the recombinant substitution variant recSerETI

Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis

Coronary Thrombolytic Properties of a Novel Recombinant Plasminogen Activator (BM 06.022) in a Canine Model

Formulation of Proteins in Vacuum-Dried Glasses. II. Process and Storage Stability in Sugar-Free Amino Acid Systems

LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulfate

The 2.3 Å Crystal Structure of the Catalytic Domain of Recombinant Two-chain Human Tissue-type Plasminogen Activator

Mapping of the catalytic site of CHO‐t‐PA and the t‐PA variant BM 06.022 by synthetic inhibitors and substrates

Tissue kallikrein effectively activates latent matrix degrading metalloenzymes

Pharmacokinetic properties of an escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits

Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA

Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli

Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors

The Effects of Tween 20 and Sucrose on the Stability of Anti‐L‐Selectin during Lyophilization and Reconstitution

The interaction of recombinant tissue type plasminogen activator and recombinant plasminogen activator (r-PA/BM 06.022) with human endothelial cells

Binding of recombinant variants of human tissue-type plasminogen activator (t-PA) to human umbilical vein endothelial cells

Pharmacokinetic and preclinical studies with reteplase

The degradation of collagen by a metalloproteinase from human leucocytes

Effect of disulfide bonds on the structure, function, and stability of the trypsin/tPA inhibitor from Erythrina caffra : Site-directed mutagenesis, expression, and physiochemical characterization

Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022

Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis

The spectroscopic analysis, inhibition and binding studies demonstrate the equivalence of Erythrina caffra trypsin inhibitor and the recombinant substitution variant recSerETI1Dedicated to Prof. Maria-Regina Kula on the ocasion of her 60th birthday1

The recombinant Escherichia coli-derived protease-domain of tissue-type plasminogen activator is a potent and fibrin specific fibrinolytic agent

spectroscopic analysis, inhibition and binding studies demonstrate the equivalence of Erythrina caffra trypsin inhibitor and the recombinant substitution variant recSerETl

A variant of tissue plasminogen activator (t-PA) comprised of the Kringle 2 and the protease domain shows a significant difference in the in vitro rate of plasmin formation as compared to the recombinant human t-PA from transformed chinese hamster ovary cells

Suchergebnisse filtern